Abstract Enolase is a multifunctional protein, which is expressed abundantly in the cytosol. Upon stimulatory signals, enolase can traffic to cell surface and contribute to different pathologies including injury, autoimmunity, infection, inflammation, and cancer. Cell-surface expression of enolase is often detected on activated macrophages, microglia/macrophages, microglia, and astrocytes, promoting extracellular matrix degradation, production of pro-inflammatory cytokines/ chemokines, and invasion of inflammatory cells in the sites of injury and inflammation. Inflammatory stimulation also induces translocation of enolase from the cytosolic pool to the cell surface where it can act as a plasminogen receptor and promote extracellular matrix degradation and tissue damage. Spinal cord injury (SCI) is a devastating debilitating condition characterized by progressive pathological changes including complex and evolving molecular cascades, and insights into the role of enolase in multiple inflammatory events have not yet been fully elucidated. Neuronal damage following SCI is associated with an elevation of neuron specific enolase (NSE), which is also known to play a role in the pathogenesis of hypoxic-ischemic brain injury. Thus, NSE is now considered as a biomarker in ischemic brain damage, and it has recently been suggested to be a biomarker in traumatic brain injury (TBI), stroke and anoxic encephalopathy after cardiac arrest and acute SCI as well. This review article gives an overview of the current basic research and clinical studies on the role of multifunctional enolase in neurotrauma, with a special emphasis on NSE in acute SCI.
Introduction
Enolase is a multifunctional glycolytic enzyme that acts as a plasminogen binding protein, and it is found to be involved in hypoxia and ischemia (Chen and Giblett 1976; Pancholi 2001; Diaz-Ramos et al. 2012) . Enolase plays multiple roles in growth control, hypoxia, immune tolerance, and allergic responses (Fan et al. 2015; Kuehn et al. 2014; Fukano and Kimura 2014) . Enolase can stimulate immunoglobulin production, which in turn may activate humoral and cellular immune responses in the host (Vermeulen et al. 2008) . Enolase is increased after injury leading to activation of endothelial cells and neutrophils through plasmin activity and PAR-2 (protease activated receptor-2) activation (Bock et al. 2015) . Enolase has also been detected on the surface of pathogens and activated immune cells, where it can serve as a plasminogen receptor and participates in systemic infection or tissue invasion (Kolberg et al. 2006; Bae et al. 2012 ). However, depending on inflammatory signals, it can be differentially localized to the cell surface, promoting a number of pathologies in injury, infection, transplantation, and autoimmunity (Pancholi 2001; Shie et al. 2014; Fan et al. 2015) . Enolase can also act as a heat-shock protein as it binds to cytoskeletal and chromatin structures, and it can play crucial roles in a variety of pathophysiological processes. Enolase expression and trafficking could also be considered as a marker of pathological stress in a wide variety of diseases (Pouw et al. 2009) .
Another important consideration is that post-translational modification of enolase is shown to affect the biological functions of enolase in the host (Diaz-Ramos et al. 2012) . Although enolase does not have classical cellular machinery for surface transport, it often appears on the cell surface through unknown mechanism(s) under inflammatory conditions. Cell surface enolase, which may also serve as a separate function in some organisms, assists in the invasion of their host cells by binding to plasminogen (Ghosh and JacobsLorena 2011 ). The bound plasminogen is then cleaved by specific proteases to generate active plasmin, which degrades ECM, facilitating pathogen invasion. Enolase interacts with urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen, and blockade of enolase reduces extracellular matrix (ECM) degradation and cell invasion (Redlitz et al. 1995; Pancholi 2001; Sawhney et al. 2015) . It has been shown that cell surface plasminogen activation in activated monocytes, B-cells, T-cells, and granulocytes, is promoted by enolase (Lopez-Alemany et al. 2003; Bae et al. 2012; Sawhney et al. 2015) . Thus, it is possible that a close association between enolase and the uPA/uPAR complex may be responsible for the presence of enolase on the cell surface.
Enolase expression is found throughout the body, however, different isoforms are found to be tissue specific. A switch from enolase-1 (α) to enolase-2 (γ) occurs in neuronal cells. Similarly, a switch from enolase-1 (α) to enolase-3 (β) occurs in muscle tissue during development in rodents. Recent studies suggest that γ-enolase or neuron specific enolase (NSE) levels in cerebrospinal fluid (CSF) can be a useful diagnostic biomarker capable of predicting complete vs. incomplete spinal cord injuries in humans (Pouw et al. 2014) . Studies in brain injury have also found increases in NSE in CSF and peripheral blood, with increases correlating to injury severity (Berger et al. 2002) . Enolase is expressed in astrocytes and oligodendrocytes (OLGs) and exerts autocrine and paracrine effects on glia, neurons, and microglia. Elevated levels of NSE are also toxic and may stimulate the expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), inducing apoptosis in neuronal cells (Fig. 1) . Surface enolase on monocytes/macrophages, microglia, and astrocytes may induce reactive oxygen species (ROS), nitric oxide (NO), as well as inflammatory cytokines (IL-1β, TGF-β, and TNF-α) and chemokines (MCP-1 and MIP-1α), has the potential to modulate diverse cellular events in secondary damage after spinal cord injury (SCI).
Individuals with SCI usually have devastating neurologic deficits and disability, and depending on severity of injury, can often lead to paralysis. (McDonald and Sadowsky 2002; Sribnick et al. 2010) . Acute SCI can be considered as a two-step process involving primary and secondary injury mechanisms. Primary injury results from external mechanical forces leading to irreversible tissue detrition and necrosis at the lesion site. Secondary injury, on the other hand, involves multiple cellular and molecular events such as: ischemia, edema, excitotoxicity, inflammation, electrolyte imbalance, free radical damage, and delayed cell death or apoptosis (Dumont et al. 2001; Oyinbo 2011; Zhang et al. 2012; Chamberlain et al. 2015) . Secondary injury develops during the days to weeks following primary injury where enolase may play a role in promoting neuronal cell death. A primary component of secondary injury, inflammation and release of toxic molecules from the injured cells, further contributes to additional neuronal and oligodendroglial cell death (Tator and Fehlings 1991; Cristante et al. 2012; Mortazavi et al. 2015) . These processes driving secondary injury may be reversible, and inhibition of enolase at multiple time points may attenuate this damage after SCI. Fig. 1 The potential adverse effects of cell surface enolase may be linked to the alterations of neuronal, glial, and immune cell functions, and induction of inflammatory responses following injury. NSE or γ-enolase expression is elevated in microglia and astrocytes following SCI. Similarly, α-enolase expression is increased in macrophages and B-cells following activation or injury. Rapid translocation of enolase from cytosol to the cell surface drives a number of events such as production of reactive oxygen species (ROS), nitric oxide (NO), inflammatory cytokines (e.g., TNF-α, IL-1β, IFN-γ, TGF-β) and chemokines (e.g., MCP-1, MIP-1α), which contribute to neuronal cell death. Macrophages, microglia, and B-cells can enhance antigen presentation, T cell activation, and production of inflammatory cytokines, which may aggravate inflammatory processes and neuronal death after injury One of the major pathologies contributing to secondary injury of SCI is the loss of OLGs, with subsequent Wallerian degeneration. OLGs are thought to be susceptible to the toxicity of the acute lesion environment after SCI as they undergo both necrosis and apoptosis in the acute phase while apoptosis may be prevalent in chronic phases of the injury (Almad et al. 2011; Li and Leung 2015) . Loss of OLGs causes demyelina t i o n a n d i m p a i r s a x o n f u n c t i o n a n d s u r v i v a l . Oligodendrocyte precursor cells (OPCs) are potential sources for replacement of OLGs after SCI (Li and Leung 2015) . It is believed that OPCs act rapidly following injuries, proliferate at a high rate, and can differentiate into myelinating OLGs. Thus, a better understanding of OPC differentiation and maturation could contribute to the development of novel therapies for SCI. It still remains unknown whether cell surface enolase on microglia disrupts the differentiation and maturation of OPCs and promotes demyelination.
Given the potential pathological role that enolase may play in neurodegeneration, studies are underway investigating how enolase inhibition affects neurodegenerative processes. Blocking enolase expression by antibody or shRNA plasmid has been shown to reduce plasmin and MMP-2/9 activation, and ECM degradation, suggesting that enolase inhibitor can be used as a modulator of inflammation. Thus, targeting cell surface enolase may offer a novel therapeutic strategy in individuals suffering from a variety of inflammatory and malignant diseases. This review article discusses the current status of a potential neurochemical biomarker NSE and its multifunctional role in astroglial and microglial activation and induction of neuronal damage in SCI.
Enolase structure, isoforms, and functions
Enolase was discovered by Lohmann and Meyerhof in 1934. It is a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. The reaction is reversible, depending on environmental concentrations of substrates. In addition to its glycolytic function, enolase plays a variety of roles in pathophysiological settings including ischemia, oncogenesis, tumor progression, and bacterial infection (Fukano and Kimura 2014) . Enolase exists as cell-type specific isoforms such as αα in most adult tissues, αγ and γγ in neurons, and αβ and ββ in muscle cells. The crystal structure of enolase at high resolution (2.25 Å) has been determined (Lebioda and Stec 1988) . Enolase can be localized in cytoplasm, nucleus, and cell surface of various mammalian cells to mediate distinct functions (Chen and Giblett 1976) . However, upon stimulatory signals, enolase can translocate to cell surface and contribute to the induction of inflammatory immune responses in the host.
Cell-surface expression of enolase is often detected on activated macrophages, microglia, neurons, and astrocytes ( Fig. 1) , which may lead to the activation of different cellular events and production of pro-inflammatory cytokines (TNF-α) and chemokines (MCP-1), and invasion of inflammatory cells (Wygrecka et al. 2009; Bae et al. 2012; Hsiao et al. 2013) . Enolase on the cell surface induces surfaceassociated proteolysis, which favors migration of phagocytic cells to the site of inflammation. Enolase also binds plasminogen at the cell surface, and increases local plasmin production, further contributing to enhanced monocyte migration through epithelial monolayers, and matrix degradation (Wygrecka et al. 2009 ). Surface enolase is also likely to concentrate plasminogen on the cell surface, which promotes pericellular plasminogen activation and ECM degradation, and increases invasion and metastasis of tumor cells (Shih et al. 2010) . NSE, which is the neuronal form of the glycolytic enzyme enolase, is found almost exclusively in neurons and cells of neuroendocrine origin (Oliva et al. 1991) . NSE influences neurotrophic activity and is believed to regulate growth, differentiation, survival and even regeneration of neurons via the activation of PI3K/Akt pathway (Fig. 2 ). It has also been shown that NSE-mediated PI3K activation regulates RhoA kinase (Hafner et al. 2012) , and the inhibition of Rhoassociated downstream kinase ROCK results in enhanced NSE-induced cellular proliferation, actin polymerization, and overall cell growth. Fig. 2 Expression of cell surface enolase promotes cell migration, survival and growth, and initiates inflammatory process after injury. Increased expression of cell surface enolase elicits pro-inflammatory responses to stimulate plasminogen/plasmin system, promoting activation of MMPs, pro-growth factors, and ECM degradation. Elevation of enolase also promotes glycolysis, cellular proliferation, and migration via the PI3K/Akt pathway. Enolase-mediated activation of PI3K also regulates RhoA kinase, which can influence actin cytoskeleton reorganization, induction of neurite outgrowth, and growth arrest in neuronal cells. Upon activation of plasmin/MMPs by increased enolase expression may also lead to MEK/ERK and Rho pathways, inducing cellular proliferation, differentiation, and migration NSE is a 78 kDa γ-homodimer and represents the dominant enolase-isoenzyme found in neuronal and neuroendocrine tissues. It is also known as enolase 2, and is encoded by the ENO2 gene in humans. A switch from α-enolase to γ-enolase also occurs in neural tissue during development in rats and primates. NSE consists of two γ subunits and converts 2-phosphoglycerate into phosphoenolpyruvate (Diaz-Ramos et al. 2012) . NSE is thought to be a marker of ischemic brain damage, and it has been shown to be elevated in stroke (Anand and Stead 2005) , traumatic brain injury (TBI) (Pleines et al. 2001; Cheng et al. 2014) , ischemiareperfusion injury (IRI) (Zhang et al. 2005) , and SCI (Cao et al. 2008; Li et al. 2014 ).
NSE expression in neuronal and glial cells
Enolase molecules are commonly known as dimers, which are composed of two of the three distinct subunits coded by separate genes originally designated as α (liver), β (muscle), and γ (brain) forms. While αα isoenzyme is present in all fetal tissues and most adult mammalian tissues, ββ and γβ forms are found predominantly in skeletal and heart muscle. β-enolase is found in skeletal muscle cells in the adult where it may play a role in muscle development and regeneration. As mentioned above, a switch from α-enolase to β-enolase occurs in muscle tissue during development in rodents. On the other hand, the γγ-enolase and αγ-enolase are frequently referred to as NSE or γ-enolase, and cell surface expression of NSE may play multiple roles in glial and neuronal activation leading to neuroinflammation. The biological half-life of NSE in body fluids is approximately 24 h. NSE expression is also detected in cultured OLGs and elevated during the differentiation of OLG precursors into mature OLGs (Krohn et al. 2015) , although it is believed to be repressed in fully mature OLGs. NSE is detectable in glial neoplasms and reactive glial cells while undergoing morphological changes (Isgro et al. 2015) . It is also expressed in astrocytes but at much lower levels than in neurons and OLGs (Isgro et al. 2015) . Cell surface enolase can drive spinal microglial activation with upregulation of major histocompatibility complex-1 (MHC-1) and MHC-II (Mueller et al. 2006; Li et al. 2013 ), which in turn may induce inflammatory responses after acute SCI. Our recent study suggests that an increased enolase expression enhances MHC-II-mediated antigen presentation by B-cells, macrophages, and dendritic cells, and also activates CD4+ T cells (God et al. 2015) . Studies have also found measurable NSE in cerebrospinal fluid (CSF) and serum, which is elevated in different inflammatory diseases involving neuronal destruction (Royds et al. 1982) . Thus, elevated NSE is sometimes considered as a valuable marker in neuronal injury.
NSE in neuroinflammation
NSE is the neuronal form of the glycolytic enzyme enolase. It is a dimeric form composed of two γ subunits that converts 2-phosphoglycerate into phosphoenolpyruvate. NSE is found almost exclusively in neurons and cells of neuroendocrine origin, and is measurable in blood and CSF (Johnsson et al. 2000) . NSE is likely to concentrate plasminogen on the cell surface and promotes pericellular plasminogen activation, ECM degradation, proliferation of inflammatory glial cells, and invasion and metastasis of tumor cells (Shih et al. 2010 ). The ECM exists in different biochemical and structural forms, and alters basic functions that are important for the inflammatory process, such as immune cell migration into inflamed tissues and production of inflammatory cytokines and chemokines.
Studies have tested many different molecules (e.g., tau protein, amyloid precursor protein, α-synuclein, etc.) in search for specific biochemical markers of brain injury with special attention on NSE and Ca 2+ -binding protein S100B (Fogel et al. 1997; Goncalves et al. 2008) . NSE is predominantly present in neurons, and it can be released into blood after brain injury (Cooper 1994) . Interactions of NSE with many different nuclear, cytoplasmic, or membrane molecules in the CNS raises the possibility that it can also interact with S100B, and proceed with the neuronal damage. It has been reported that S100B protein is mainly expressed and secreted by astrocytes in the central nervous system (CNS) (Tramontina et al. 2008; Dang et al. 2014) , and frequently detected in a variety of pathologic insults to the brain, where NSE is also elevated. Additionally, increased plasma concentrations of NSE and S100B have been detected in patients with SCI (Woodcock and Morganti-Kossmann 2013) . Since S100B negatively regulates astrocytic and microglial responses to neurotoxic agents and causes neuronal death (Sorci et al. 2013; Dang et al. 2014) , it may be interesting to look at whether regulation of NSE influences S100B and protects neurons against apoptosis.
Although enolase functions extend beyond glycolytic activity, it lacks traditional sorting signals. Thus, the question remains as to how this protein becomes surface exposed and play multiple roles in hypoxia, ischemia, and possibly neuronal death after SCI. Cell surface enolase activates plasminogen, which is a serine protease present in serum as an inactive proenzyme, and is converted by tissue-type plasminogen activator (tPA) or urokinase plasminogen activator (uPA) to active plasmin (Hsiao et al. 2013) , and to degrade ECM proteins (Fig. 2) . Then plasmin can degrade fibronectin, penetrate the endothelium, and activate matrix metalloproteinases (MMPs).
A number of studies suggest that MMPs are instrumental in the production and maintenance of a pro-inflammatory microenvironment (Svedin et al. 2007; Manicone and McGuire 2008; Leonardo and Pennypacker 2009) , which upregulates NSE and promotes ECM degradation, aggravating ischemic neuropathology. Thus, therapies targeting ECM degradation and progressive neuroinflammation could be designed by inhibition of NSE.
Cell surface enolase also influences MMPs that can help process the inflammatory cytokines TNF-α and IL-1β to their biologically active forms (Gearing et al. 1994; Schonbeck et al. 1998 ), which in turn may further enhance inflammatory responses. Both MMP-2 and MMP-9 play important roles in the inflammatory process (Bruschi et al. 2014) ; thus, targeting enolase may be considered for limiting ECM-and MMPmediated damages after injury.
NSE in other acute injuries to CNS
NSE is believed to be an important marker that directly assesses functional damage to neurons. NSE levels are often elevated in patients with CNS disorders associated with serious secondary brain injury. Serum NSE has also been tested as a marker of brain injury after global cerebral ischemia, and found to be markedly elevated, suggesting that detection of NSE is a valuable diagnostic tool in clinical management in cerebral ischemia and can be a prognostic parameter during the post-ischemic course (Horn et al. 1995) . NSE concentrations have also been found to be elevated in rat CSF after occlusion of the middle cerebral artery where sham operated animals showed only minimum damage and base level NSE at the site of surgery (Hardemark et al. 1988) . Thus, NSE is now a known biomarker of ischemic brain damage and has already been evaluated in TBI (Pleines et al. 2001) , stroke (Anand and Stead 2005) , and anoxic encephalopathy after cardiac arrest (Martens et al. 1998; Pfeifer et al. 2005) .
NSE levels are persistently elevated in TBI patients (Berger et al. 2002; Cheng et al. 2014 ), although it is not always used as a biomarker in clinical practice. A Similar observation has been reported by another group where NSE was measured in CSF samples from 23 infants and children with severe TBI (Varma et al. 2003) . This study detected 10-fold increase in NSE (100.62 ± 17.34 ng/ml vs. 8.63 ± 2.76 ng/ml, p = 0.0002) after TBI in infants and children. It has also been shown that NSE levels are relatively low at the beginning of ischemic brain injury, with low predictive power in the first 6 h. However, detection of NSE can be useful if measured after 24-48 h of TBI (Bottiger et al. 2001; Rosen et al. 2001) . Another study has found that elevated levels of NSE can be detected at an earlier time, and could be used as a prognostic marker (Rech et al. 2006) . In that study, NSE levels were measured at any time between 12 and 36 h, and the authors were able to detect NSE levels as a marker of prognosis after cardiac arrest. This was consistent with previous findings (Fogel et al. 1997; Schoerkhuber et al. 1999) , where NSE levels were shown to be higher and correlated with a worse outcome. Significantly increased NSE levels were also found in a study using ischemic stroke patients (n = 90) as compared to controls (Pandey et al. 2011) . Similarly, serum NSE levels are also thought to be important in the patients with acute intracerebral hemorrhage (ICH), as it is closely related to the volume of hemorrhage and the condition of the injury. A recent study analyzed the expression profile of NSE in patients with intracerebral hemorrhage (ICH) at 24 h (Varma et al. 2003) , and found that NSE concentrations were markedly elevated in these patients, suggesting that higher levels of serum NSE could be associated with poor outcome in ICH. As mentioned above, NSE is localized in neurons, and secreted into the blood and CSF at the time of neural injury. Like TBI, ischemia, and ICH, NSE levels are increased in subarachnoid hemorrhage (SAH) patients. Using 71 patients, a significant association between higher levels of NSE and worse outcomes has recently been reported (Tawk et al. 2015) , suggesting that NSE may hold promise for screening SAH patients.
NSE expression is upregulated in acute SCI
SCI is a devastating neurotrauma whose progressive pathological changes include complex and evolving molecular cascades (Bragge et al. 2015; Chamberlain et al. 2015) , and insights into the alterations of these dysfunctions have not been fully elucidated. Neuroprotective agents (e.g., methylprednisolone, gacyclidine, thyrotropin releasing hormone, nimodipine, etc.) against secondary injury in SCI, together with neuroregenerative agents (e.g., gangliosides, Rho antagonist, anti-Nogo antibodies, acidic fibrobast growth factor) have been used in different clinical settings of SCI with mixed outcomes (Hawryluk et al. 2008; Bragge et al. 2015; Chamberlain et al. 2015) . In spite of these studies, there is currently no FDA approved pharmacotherapeutic available for the treatment of SCI. We recently reported the potential beneficial effects of estrogen, which is an important neuroprotective agent in the treatment of SCI and TBI (Chakrabarti et al. 2015; Chakrabarti et al. 2014) . Thus, the underlying pathophysiology of SCI with special emphasis on multimodal therapy targeting novel neuroprotective as well as neurogenerative agents should be explored.
The expression levels of enolase have been tested in adult rat spinal cord following contusion injury . This study showed that enolase expression significantly increased after SCI with a peak increase at day 5, and then returned to a level seen in sham-operated animals. These data suggest that enolase protein expression is upregulated after SCI, which could activate many different inflammatory pathways leading to long-term secondary injury in the host. An increased level of enolase was also detected in both grey matter and white matter subjects in that study. Further study with specific markers for neurons, astrocytes and microglia in both sham and injured sections of SC has confirmed the changes of enolase expression after SCI. This group also performed coimmunofluorescence studies for detecting localization of enolase and determining expression of neuronal (NeuN), astroglial (GFAP), and microglial (CD11b) markers after SCI . Interestingly, the investigators have found that enolase levels were markedly increased in astrocytes and microglia after injury but not in neurons when compared with sham-operated spinal cord, suggesting that differential activation of enolase in the brain might induce different pathologies after injury. Since enolases are metalloenzymes and can function as plasminogen receptors (Floden et al. 2011) , surface expression of enolase in glial cells may have the ability to initiate MMP activation cascade by cleaving pro-MMP (Lo et al. 2003) . Down regulation of enolase on immune cells as well as neuronal and glial cells may be a new avenue for suppressing neuroinflammation in secondary injury of SCI.
Regulation of NSE after SCI
Accumulating evidence suggests contribution of immune cells to the SCI pathology and repair. The infiltration of polymorphonuclear leucocytes (PMNs), macrophages/microglia, Bcells and T-cells exacerbates poor recovery from SCI (Popovich et al. 1996; Saville et al., 2004; Jones et al. 2005; Nguyen et al. 2007) , where elevated NSE may play critical roles in the inflammatory process. As mentioned above, NSE expression is increased in astroglial and microglial cells after SCI , which may activate inflammatory cytokines and chemokines leading to axonal damage and neuronal death (Fig. 3) . Our group has shown that calpain content progressively increased in the SCI lesion by 22 % at 30 min to 91 % at 4 h after trauma compared to control and then decreased but remained elevated for up to 72 h following injury (Banik et al. 1997) . Like calpain, NSE is also elevated early in injury and is involved in the breakdown of cytoskeletal proteins after injury. An effective enolase inhibitor ENOblock has recently been discovered as the first non-substrate analog inhibitor that directly binds to the enzyme (Jung et al. 2013) . While enolase inhibitors are thought to be anti-diabetic and anti-metastatic, ENOblock has only been tested in a preclinical xenograft model. So far, clinical trials of this drug have not been performed.
Our unpublished data indicate that inhibition of enolase by ENOblock attenuates calpain levels in glial and immune cells, suggesting that ENOblock treatment may help decrease inflammatory events in SCI and brain injury. Thus, it may be interesting to look at whether use of ENOblock alone or in combination with some of these available therapeutic approaches additively or synergistically prevent secondary damages for improving locomotor function in chronic SCI. It is possible that increased NSE expression in neuronal and glial cells after SCI , will activate inflammatory cascades, and enolase inhibition by the novel small molecule ENOblock may attenuate inflammation in secondary damages of SCI (Fig. 3) . Studies in our laboratory are underway to determine the effect of ENOblock after SCI in rodents.
Conclusions
This review summarizes the detrimental role of NSE primarily in the setting of acute SCI. NSE has the potential to be an important biomarker for neuronal death in different CNS injuries. Enolase also has neurotrophic properties on a broad spectrum of CNS neurons. However, current studies strongly implicate that targeting NSE with enolase inhibitor ENOblock can be an important therapeutic strategy for prevention of inflammation and neurodegeneration in acute SCI. Further, combination of ENOblock and calpain inhibitor may work additively or synergistically for very effective neuroprotection with subsequent improvements in locomotor function in both acute and chronic SCI in experimental animals. Success of this strategy in preclinical models of SCI may provide for a successful clinical candidate to provide an effective therapeutic for individuals suffering from SCI.
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Disclosures The authors have no financial conflict of interest. Fig. 3 Elevation of neuron-specific enolase (NSE) following SCI. Cell surface expression of NSE in neuronal and glial cells is detrimental to neuronal survival as it promotes inflammation after SCI. Treatment with the enolase inhibitor ENOblock may attenuate inflammatory events in acute SCI and reduce secondary damages of the injury, supporting neuronal survival
